Healthcare Providers and Services
Company Overview of Janssen Inc.
Janssen Inc. distributes healthcare products. The company offers products for mental wellness, anemia and fatigue, kidney disease, women’s health, wound healing, Alzheimer disease, eldercare, psychiatry, neurology, dementia, attention deficit hyperactivity disorder, immunology, pain management, gastroenterology, infectious diseases, and urology. It also offers oral medications for the treatment of HIV infection in combination with other antiretroviral agents. Janssen Inc. was formerly known as Janssen-Ortho Inc. The company was founded in 1941 and is based in Toronto, Canada with a division office in Montreal. Janssen Inc. operates as a subsidiary of Johnson & Johnson.
19 Green Belt Drive
Toronto, ON M3C 1L9
Founded in 1941
Key Executives for Janssen Inc.
Janssen Inc. does not have any Key Executives recorded.
Janssen Inc. Key Developments
Janssen Inc. Recalls One Lot of Ortho-Cept Tablets (28 Day)
Apr 22 15
Health Canada is advising consumers that Janssen Inc. is recalling one lot of Ortho-Cept tablets (28 day), an oral contraceptive, due to the potential low potency of the two active ingredients. This may result in reduced effectiveness of the product and in some cases, a possible risk of unplanned pregnancy. The risk associated with an unplanned pregnancy is higher for certain groups of women, such as those who have been advised against becoming pregnant for medical reasons or women who have been advised not to use very low dose formulations. DIN: 02042533, strength: 0.15 mg of desogestrel and 0.03 mg ethinyl estradiol, exp. Date: Setember 2015. Who is affected: consumers who have purchased or used Ortho-Cept tablets (28 day), lot 13DM732. What consumers should do: if consumers are unable to determine the lot number of medication, contact the pharmacy from where it was received to confirm the lot number; speak to healthcare provider about an alternative oral contraceptive as Ortho-Cept is being discontinued and will no longer be available on the Canadian market; use another form of reliable contraception and discontinue the use of the Ortho-Cept once consumer is safely switched over to the alternative; return unopened packages to pharmacist; report any adverse events to Health Canada. Health Canada is monitoring the recall and the implementation of appropriate corrective and preventative actions by Janssen Inc. Should new information be identified, Health Canada will update Canadians.
Ontario Institute for Cancer Research Extends Collaboration with Janssen Inc. to Develop Clinical Trials for Prostate Cancer
Feb 25 15
The Ontario Institute for Cancer Research (OICR) is extending its collaborative research partnership with Janssen Inc. to develop more multi-centre clinical trials and other translational research projects that address important clinical questions in prostate cancer. The new funds will be made available to qualifying researchers at cancer centres across Canada who are addressing important clinical questions in prostate cancer. The funding will be dispersed to researchers through the Canadian Cancer Clinical Trials Network, which is based at OICR, through an open application process.
Janssen Inc. in Collaboration with USAID to Expand Access to Multidrug-Resistant TB Therapy
Dec 15 14
Janssen Inc. signed a memorandum of understanding with the US Agency for International Development (USAID) regarding the firm's commitment to tackle multidrug-resistant tuberculosis (MDR-TB). Based on the terms of the agreement, Janssen will provide approximately 30,000 courses of its MDR-TB drug Sirturo (bedaquiline), which is worth an estimated USD 30 million, to USAID that consequently will work with national TB programmes to provide access to the treatment using certain eligibility criteria.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|